Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000608

Drug Information
NameEntacapone    
SynonymsD00781; C07943; ENTACAPONE; Novartis brand of entacapone; CHEMBL953; Comtan; HMS2089O16; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; COM-998; Entacapone (JAN/USAN/INN); CID5281081; Entacaponum [INN-Latin]; CHEBI:4798; DB00494; Orion brand of entacapone; OR 611; MolPort-003-847-054; AC-393; Comtess; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-; Comtan (TN); Entacaponum; LS-123327; OR-611; NCGC00164555-01; LS-172316; BIDD:GT0026; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; C14H15N3O5; 116314-67-1; Entacapone [USAN:INN]; AC1NQY02; Entacapona; UNII-4975G9NM6T; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; KB475572; 130929-57-6; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; Entacapona [INN-Spanish]; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; C071192    
Trade NameComtan, Stalevo    
CompanyNorvatis Phamaceuticals Corporation    
IndicationParkinson's diseaseApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntiparkinson Agents    
CAS NumberCAS 130929-57-6
FormularC14H15N3O5    
PubChem Compound IDCID 5281081.    
PubChem Substance IDSID 10145.    
ChEBI4798;    
SuperDrug ATC IDN04BX02;    
SuperDrug CAS ID116314671;    
TargetCatechol-O-methyl-transferaseInhibitor[2][3]
Ref 1Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 2Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. To Reference
Ref 3Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543